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ﻱﺮﻜﺴﻟﺍﺀﺍﺩﻦﻣﻲﻧﺎﺜﻟﺍﻉﻮﻨﻟﺍﺝﻼﻌﻟﻡﺪﻟﺍﺮﻜﺴﻟﺔﻀﻓﺎﺨﻟﺍﺔﻳﻮﻤﻔﻟﺍﺔﻳﻭﺩﻷﺍﻡﺪﺨﺘﺴﺗ
ﺮﺜﻛﻷﺍﻡﺪﻟﺍﺮﻜﺴﻟﺔﻀﻓﺎﺨﻟﺍﺔﻳﻭﺩﻷﺍ.ﺎﻬﻟﺎﻤﻌﺘﺳﺍﺔﻟﻮﻬﺳﻭﺎﻬﺘﻴﻠﻋﺎﻔﻟﺍﺮﻈﻧ،ﺩﻮﻘﻋﺬﻨﻣ
ﺔﻳﻭﺩﻷﺍﻩﺬﻫﻰﻠﺗ.ﺎﻣﺎﻋ٠٥ﻦﻣﺮﺜﻛﺃﺬﻨﻣﺎﻳﺭﻮﻳﻞﻴﻧﻮﻔﻠﺳﻭﻦﻴﻣﺭﻮﻔﺘﻣﻲﻫﺔﺑﺮﺠﺗ
ﻦﻳﺪﻟﻭﺯﺎﻴﺛﻭ،ﺕﺍﺪﻴﻨﻴﻠﺠﻟﺍﻞﺜﻣﻡﺪﻟﺍﺮﻜﺳﺾﻔﺧﺔﻳﻭﺩﺃﻦﻣﻯﺮﺧﺃﺕﺎﺒﻛﺮﻣﻢﻳﺪﻘﺗ
ﺕﺎﻄﺒﺜﻣﻭ،٤eﺰﻳﺪﺘﺒﺑﻞﻳﺪﺘﺒﺒﻳﺩﺕﺎﻄﺒﺜﻣﻭ،ﺰﻳﺪﻴﺳﻮﻛﻮﻠﺟﺎﻔﻟﺃﺕﺎﻄﺒﺜﻣﻭ٬ﺕﺎﻧﻮﻳﺩ
ﻞﻀﻔﻤﻟﺍﺀﺍﻭﺪﻟﺍﻦﻴﻣﺭﻮﻔﺘﻤﻟﺍﺮﺒﺘﻌﻳﻭ.٢ـــﺯﻮﻛﻮﻠﺟeﻡﻮﻳﺩﻮﺼﻟﻙﺭﺎﺸﻤﻟﺍﻞﻗﺎﻨﻟﺍ
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years. These agents were followed by the introduction of
other antihyperglycaemic agents such as glinides (GLN),
thiazolidinediones (TZD), alpha-glucosidase inhibitors
(AGI), dipeptidyl peptidase-4 inhibitors (DPP-4I), and
sodiumeglucose cotransporter-2 inhibitors (SGLT2I).
MET is recognized as the drug of choice for monotherapy
unless contraindicated or unwanted side effects occur.
SU-induced hypoglycaemia is losing ground to various
new agents, but the generic formulae of SU together with
MET are cheap and effective. The cardiovascular hazards
of several agents are a major concern to physicians and
legislating bodies. In choosing antihyperglycaemic agents
for dual or triple therapy, the treating physician must
keep in mind the health status of the patient, medication
side effects, cost, and patient preference. This review
addresses the advantages and disadvantages of a range of
antihyperglycaemic agents and their applications in
monotherapy or combination therapy.
Keywords: Cardiovascular events; Drug safety; Glycaemic
management; Hypoglycaemic agent; New antidiabetic
therapy
 2016 The Author.
Production and hosting by Elsevier Ltd on behalf of Taibah
University. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Oral antihyperglycaemic agents have been the mainstay
of treating type 2 diabetes mellitus (T2DM) for numerous
decades given their efficacy and convenience. Metformin
(MET) and sulphonylureas (SU) have been in use for more
than 50 years, and their major side effects are widelyhis is an open access article under the CC BY-NC-ND license
16/j.jtumed.2016.02.001
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tion of many classes of these agents, and their optimal use
and side effects are gradually recognized. Seven approved
major classes of oral antihyperglycaemic agents are
currently available: MET, SU, glinides (GLN), thiazolidi-
nediones (TZD), alpha-glucosidase inhibitors (AGI),
dipeptidyl peptidase-4 inhibitors (DPP-4I), and the most
recent sodiumeglucose cotransporter-2 inhibitors (SGLT-
2I). This review summarizes the characteristics of each class
and their use in T2DM management. The cardiovascular
safety of these medications has received more attention in
the last few years after the United States Food and Drug
Administration (FDA) reported unexpected cardiovascular
outcomes and made new requirements for licensing new
antidiabetic drugs. These outcomes are discussed in the
section on TZD.
Metformin
Traditionalmedicine usedFrench lilac for treating diabetes
for centuries, and guanidine compounds were derived from its
extract in 1920s.1 These compounds exhibited hypoglycaemic
effects in animals but were later withdrawn due to
hepatotoxicity in patients. The biguanides, phenformin and
MET are derived from guanidines and were introduced in
1950’s.2 However, phenformin was withdrawn in the late
1970s, as it was linked to fatal lactic acidosis.3
Mechanism of action and efficacy
Metformin works by reducing hepatic gluconeogenesis
and increasing glucose uptake in the peripheral tissues,
especially in muscles,4,5 thus improving insulin sensitivity.
As it does not stimulate insulin secretion, metformin
monotherapy rarely causes hypoglycaemia. Metformin
also enhances the action of glucagon-like-peptide-1 (GLP-
1), but the clinical significance of this agent is not
established.6
Metformin is recognized as the first agent to be used as
monotherapy with life-style modification to treat T2DM
unless intolerance or a contraindication for its use is noted.7,8
The United Kingdom Prospective Study (UKPDS)
demonstrated that overweight patients allocated to the MET
group exhibited reduced median HbA1C compared with the
conventional group (7.4% vs 8%), with 32% risk reduction
for any diabetes related endpoints.9 A systemic review
analysing the results of 15 controlled studies on treatment
with MET versus control reported a weighted mean
absolute difference (WMAD) in HbA1C levels
of 1.14%.10 Many reports refer to a reduction of HbA1C
by 1e2%.11 Despite this finding, metformin gradually loses
efficacy with a cumulative incidence of secondary failure as
a monotherapy of 21% at 5 years, which is better compared
with SU.12 However, starting MET monotherapy in T2DM
was less likely to require intensification by another agent
compared with SU, TZD, or DPP-4I.13
Analysis of 8 controlled trials reported the weighted mean
difference (WMD) in body weight between the treatment and
control as 0.3 kg.10 Although some studies reported weight
reduction, the treatment is generally considered weight
neutral.11Side effects and contraindications
The most frequently reported side effect, which may force
the patient to discontinue usage, is gastrointestinal (GI)
upset, which could be due to the release of 5-
hydroxytryptamine and other substances within the
duodenal mucosa.14
GI upset may be managed by a starting dose of 500 mg
daily with meals. The dose is then increasingly titrated by
500 mg every 1e2 weeks in two to three divided doses until
the desirable dose is achieved. Another method involves the
use of the extended release formula of MET. The extended
release formula was well tolerated by 97.4% of patients in a
study of 3556 patients.15 Vitamin B12 deficiency may develop
with prolonged MET use, especially in elderly diabetic
patients administered high doses.16
Lactic acidosis is a lethal complication that causes the
withdrawal of phenformin, but this condition rarely occurs
with MET. An extensive systematic review showed no
increase in lactic acidosis in 70,490 MET users years
compared to non users.17 However, one should avoid
using MET in conditions that predispose to lactic
acidosis, such as severe renal failure. Metformin should
be avoided in patients with chronic liver disease, heart
failure, renal failure, sepsis and shock.11 However, there
is debate about avoiding MET in heart failure. Analysis
of nine cohort studies concluded that MET is as safe as
other oral hypoglycaemic agents in patients with heart
failure.18
The FDA advises to avoid MET if serum creatinine is
1.5 mg/dl in males and 1.4 mg/dl in females.19 However,
an observational study over approximately 4 years revealed
no increase in the risk of severe side effects, including
acidosis, in patients administered MET with a creatinine
clearance of 30e45 ml/min/1.73 m2.20
The FDA also advises to avoid MET before, during and
48 h following radiologic studies involving IV iodinated
contrast.19 However, the American College of Radiology
does not recommend holding MET dosing in relation to IV
iodinated contrast studies if the patient does not have acute
kidney injury and has an eGFR 30 ml/min/1.73 m2 nor in
relation to gadolinium in the typical dose range of 0.1e
0.3 mmol/kg.21
The side effects of MET are summarized in Table 1.
Cardiovascular safety
Metformin was associated with 42% reduction in
diabetes-related deaths and 36% reduction of all-cause
mortality in the UKPDS.9 In the intensive blood-glucose
control group, patients treated with MET exhibited a
greater effect for all-cause mortality, stroke and diabetes
related endpoints compared with those treated with SU. The
reduction of myocardial infarction and mortality gained by
MET use in overweight patients in the UKPDS was main-
tained 10 years after the end of the study.8
Dosage
Table 2 shows the dose of MET and relation to food
intake.
Table 1: Side effects of antihyperglycaemic agents.
Drug Body weight Hypoglycaemiaa Others
Metformin Neutral Neutral GI upset, rarely lactic acidosis. Avoid in
severe renal and heart failure.
Sulphonylureas Increased weight Yes Questionable cardiovascular safety,
care in liver disease.
Glinides Increased weight Yes Drug interactions, upper respiratory infections.
Thiazolidinediones Increased weight Neutral Oedema, heart failure, bone loss
Alpha-glucosidase inhibitors Neutral Neutral GI upset. Avoid in liver cirrhosis and
inflammatory bowel disease.
Dipeptidyl peptidase-4 inhibitors Neutral Neutral Angio oedema, pancreatitis.
Sodiumeglucose
cotransporter-2 inhibitors
Decreased weight Neutral Genitourinary infections, dehydration
GI: Gastrointestinal.
a Hypoglycaemia in monotherapy.
Oral antihyperglycaemic agents 319Sulphonylureas
The discovery of sulphonamides marked the beginning of
the SU era. In 1942, a sulphonamide developed to treat
typhoid fever was found to cause hypoglycaemia in animals
and caused severe hypoglycaemia in patients.1,22 This
discovery was followed by the development of tolbutamide
in 1956 and chlorpropamide thereafter. First-generation
SUs, namely, tolbutamide and chlorpropamide, are not
currently used and were replaced by second generation SUs,
including glibenclamide, glipizide, gliclazide, and
glimepiride.Mechanism of action and efficacy
Sulphonylureas exert their hypoglycaemic effect by
increasing second phase insulin secretion.23 The action of
SUs may be longer than their half-life given the biologic
activity of their metabolites.
Sulphonylureas are effective antihyperglycaemic agents
that reduce HbA1C by greater than 1% in monotherapy
regimens.11 Analysis of 11 controlled studies of monotherapy
with SU against control found that the WMAD in HbA1C
was 1.52.10 The UKPDS demonstrated the effectiveness
of SU over a 10-year period. In this study, the intensive
group achieved an HbA1C of 7% with a 25% reduction in
microvascular complications and 10% reduction in any
diabetes-related death. However, no beneficial effects on
macrovascular complications were noted.24 Despite their
efficacy, the efficacy of sulphonylureas in monotherapy is
gradually reduced. The cumulative incidence of secondary
failure for glibenclamide was 34% at 5 years.12
Side effects and contraindications
The effectiveness of oral administration, the convenient
once or twice daily dosing and greater than 50 years of testing
make SUs appealing oral antihyperglycaemic agents, but
their efficacy is hampered by side effects. The most important
side effects include hypoglycaemia and weight gain. In the
intensive group of the UKPDS, major hypoglycaemia was
noted to be 1% per year in the chlorpropamide group, 1.4%
in the glibenclamide group and 1.8% in the insulin group,with significant corresponding increases in weight of 2.6 kg,
1.7 kg and 4 kg, respectively.24 The hypoglycaemia may be
characterized as late postprandial or fasting the second
phase of insulin secretion is stimulated. Hypoglycaemia
may follow exercise as with insulin and other insulin
secretagogues. As SUs are metabolized in the liver, they
must be administered with caution in patients with liver
dysfunction.25
Treating physicians may be concerned about using SU if
the patient experienced a previous allergy to sulphonamides.
One report suggested that the determinant of type 1 allergic
reactions to sulphonamides is the N1 heterocyclic ring, which
is lacking in non-antibiotic sulphonamides, and that SUs
may be used in such patients.26
However, if a patient experienced a serious reaction, such
as Steven-Johnson’s syndrome, it may be better to avoid SUs
as the reaction may be T-cell mediated. The side effects of SU
are summarized in Table 1.
Cardiovascular safety
Although the UKPDS reported reduced mortality in the
SU arm of intensive treatment, many authorities are con-
cerned that SUs have not been subject to rigorous cardio-
vascular evaluation.27 This concern was raised as early as
1970 when a report from the University Group Diabetes
Program (UGDP) found that the mortality of non-insulin-
dependent patients treated with tolbutamide was approxi-
mately 2 1/2 that of those treated with diet alone.
27,28
In the Diabetes Audit and Research in Tayside Scotland
study (DARTS), the adjusted relative risks of mortality and
cardiovascular mortality in patients on SU monotherapy
were 1.43 (95% CI 1.15e1.77) and 1.7 (95% CI 1.18e2.45),
respectively.29 Similarly, in a cohort study of 98,665 veterans
on SU monotherapy, the adjusted hazard ratio of CVD
events was 1.21 (95% CI 1.13e1.30) compared with
155,025 patients on MET.30
The adjusted hazards ratio (HR) of death in patients
administered high doses of glibenclamide monotherapy was
1.3 (95% CI 1.2e1.4) compared with those on lower doses.31
Conversely, the Action in Diabetes and Vascular disease:
Preterax and Diamicron Modified release Controlled
Evaluation (ADVANCE) trial reported no increase in
major macrovascular events or death risk in patients on
M.S. Alhadramy320modified release gliclazide and other agents in the intensive
therapy arm that lowered HbA1C to 6.5%. However,
macrovascular and microvascular events and death were
increased in patients who had severe hypoglycaemia.32
This question should be settled by more rigorous studies.
Metformin remains the first drug of choice for initiating
T2DM treatment.Dosage
The doses of different SUs and relation to food con-
sumption are presented in Table 2. It is suggested that the
therapeutic effect of SU may be achieved by doses lower
than the specified maximum dose. For example, glipizide
doses greater than 10 mg daily do not offer additional
hypoglycaemic effects.33 The American Association of
Clinical Endocrinologists/American College of
Endocrinology (AACE/ACE) recommended adding a
hypoglycaemic agent from a different class if blood glucose
is not controlled by a submaximal dose of insulin
secretagogues rather than using the maximal dose.34
Glibenclamide and its metabolites may accumulate in
patients with chronic kidney disease (CKD), and glibencla-
mide is associated with prolonged hypoglycaemia in such
patients.35 Thus, it is not recommended for patients with
CKD. Severe hypoglycaemia as a result of glimepiride has
been described in 37 patients with creatinine clearances of
38  23 ml/min,36 but the National Kidney Foundation
(NKF) advises to start with a dose of 1 mg in patients with
CKD instead of avoiding its use.37
The metabolites of gliclazide are inactive. Thus, hypo-
glycaemia is expected to occur less frequently in CKD pa-
tients administered gliclazide compared with glibenclamide
and glimepiride.35 The NKF advises no dose change in CKDTable 2: Dose and monthly cost of antihyperglycaemic agents.
Medication Adult daily dose
Metformin: Immediate release 500 mg twice daily
Maximum 3 g in 3 doses
Metformin: Extended release 750 mg once daily
Maximum 2 g
Glibenclamide: Immediate release 1.25e20 mg daily
Doses  10 mg: divided twice da
Glipizide: Immediate release 2.5e40 mg
Doses  15 mg: divided twice da
Gliclazide: Immediate release 80e320 mg daily
Doses  160 mg: divided twice d
Gliclazide: Extended release 30e120 mg once daily
Glimepiride: 1e8 mg OD
Repaglinide: 0.5e4 mg with meals
Pioglitazone: 15e45 mg OD
Rosiglitazone 4e8 mg in 1 or 2 daily doses
Acarbose: 25e100 mg
Sitagliptin 100 mg daily
Saxagliptin 2.5e5 mg
Vildagliptin 50 mg BID
Linagliptin 5 mg twice daily
NA: Not available in KSA. OD ¼ once daily. Cost calculated for 1 m
SR ¼ Saudi Riyals; 3.75 Riyals ¼ 1 US Dollar.patients. However, one has to observe patients with end stage
renal failure carefully if gliclazide is administered. Glipizide
is metabolized in the liver to inactive metabolites and is
unlikely to produce hypoglycaemia in CKD patients. This
drug is endorsed by the NKF as the SU of choice for
patients with CKD. It seems logical that such patients
experience better results with glipizide or gliclazide rather
than glimepiride, which has been associated with severe
hypoglycaemia in this population.36
Glinides
Repaglinide was the first member of this group, which was
approved by the FDA in December 1997.38 Nateglinide was
approved in December 2000.
Mechanism of action and efficacy
This group of insulin secretagogues works through
binding sites on beta cells that are both distinct and similar to
those of SU.39 These drugs work by stimulating first-phase
insulin release but not second-phase release. Thus, these
drugs are less likely to produce late or fasting hypoglycaemia
compared with SUs.40 These drugs exert this effect as they
close the potassium channels of the beta cell and open the
calcium channel, thus inducing insulin exocytosis.39
Repaglinide has a dose-dependent, rapid onset mecha-
nism of action when taken 15 min before meals. Within
30 min of starting a meal, repaglinide produced a relative
increase of insulin up to 150% with no residual effects 4 h
later.41
Repaglinide is effective as monotherapy, reducing
HbA1C by 1.14% in a trial with flexible meal dosing for 16
weeks.42Food effect Brand
cost (SR)
Generic
cost (SR)
During or after meals 60.00 21.00
With evening meals 75.00 NA
ily
Taken with food 98.00 36.00
ily
Take 30 min before meals NA NA
aily
Taken with food NA 70.00
Taken with food 102.00 NA
Take with food 142.00 71.00
15e30 min before meals 206.00 NA
Regardless of food 139.00 NA
Regardless of food NA NA
At the beginning of each meal 82.00 NA
Regardless of food 150.00 NA
Regardless of food 140.00 NA
Regardless of food 150.00 NA
Regardless of food 113.00 NA
onth supply of maximum dose.
Oral antihyperglycaemic agents 321In a meta-analysis of four trials, repaglinide treatment
reduced HbA1C by a WMAD of 1.32% compared with
controls.10 However, the durability GLN hypoglycaemic
benefits in monotherapy is not substantial. In a follow-
up of new users up to 5.5 years, the HR for GLN fail-
ure compared with metformin was 1.66 (95% CI 1.37e
2.0).43
This group is especially helpful when meals are irregular
or unpredictable (e.g., elderly patients or patients fasting for
Ramadan). However, the frequent dosing may be a draw-
back for some patients.
Side effects and contraindications
Similar to all insulin secretagogues, repaglinide may
produce weight gain and hypoglycaemia at a frequency
comparable to that of SU.44 Repaglinide may also cause
upper respiratory tract infections with a frequency similar
to that observed with SU.45
Repaglinide is contraindicated in combination with
gemfibrozil. This combination caused a significant increase
in repaglinide exposure, but this effect is not observed with
fenofibrate.46 This class should be used with caution in the
presence of liver disease.11 Repaglinide side effects are
summarized in Table 1.
Cardiovascular safety
Glinides have not been subjected to large prospective
studies to verify their cardiovascular safety. A large nation-
wide study of more than 100,000 subjects found that the
mortality and vascular risk of repaglinide monotherapy in
patients with and without previous myocardial infarction did
not statistically differ from MET.47
One study found that Mg ADP augments the inhibitory
effect of repaglinide on potassium ATP channels on the beta
cells and smooth muscle but not on myocardial cells. The
authors suggested that this effect could explain the absence
of cardiovascular side effects with repaglinide.48
Dosage
The dose of repaglinide and relation to food are presented
in Table 2.
Repaglinide is exclusively metabolized in the liver to
inactive metabolites and secreted in the bile. Approximately
8% is excreted in the urine.45 Thus, if the liver function is
normal, the risk of hypoglycaemia in CKD patients is
reduced.
Repaglinide may be used in patients with chronic kidney
disease, but the NKF advises starting with a 0.5 mg does
before each meal in patients with a GFR30 ml/min/1.73 m2
and gradually increasing the dose.37
Thiazolidinediones
Glucose tolerance was reportedly improved in diabetic
patients on clofibrate as early as 1963.49 This finding lead
to the discovery of ciglitazone, the first drug of this
group of medications in Japan in 1970s. However,
ciglitazone was not marketed due to side effects inanimals.50 Troglitazone was introduced in the U.S.A. in
1997 followed by the approval of rosiglitazone and
pioglitazone in 1999.
Troglitazone was withdrawn in 2000 because it was
associated with hepatic toxicity.51
Mechanism of action and efficacy
Thiazolidinediones are agonists of peroxisome
proliferation-activated receptor gamma (PPARg), which is a
determinant of insulin sensitivity.50 Thus, thiazolidinediones
increase glucose uptake by skeletal muscles and adipose
tissue and suppress hepatic gluconeogenesis.52
Thiazolidinediones are effective in reducing blood
glucose. In a systematic review of nine controlled trials of
pioglitazone monotherapy versus control, thiazolidinediones
reduced HbA1C with a WMAD of 0.97 (95% CI 1.18 to
0.75).10 The corresponding figures for eight controlled trials
of rosiglitazone versus control were 1.16 (1.39 to 0.92).
Pioglitazone monotherapy reduced HbA1C by 1e1.6%
compared with placebo in a randomized trial.53
An addition study of rosiglitazone versus placebo for 24
weeks revealed a reduction of mean HbA1C of 1.2 and 1.5%
for doses of 2 and 4 mg twice daily, respectively.54 This class
may require approximately 3 months to achieve its maximum
effect.55 Thus, HbA1C measurement is not reliable during
this initial period.
The durability of the effect in monotherapy was 85% at 5
years, which is better than that of MET and of SU.12 One of
the advantages of this class is that they do not tend to
produce hypoglycaemia when administered as monotherapy.
Side effects and contraindications
One of the major side effects of TZDs is weight gain.
Over 5 years, the average weight gain with rosiglitazone was
4.9 kg, whereas glibenclamide caused a weight gain of 1.6 kg
in the first year and stabilized thereafter.12 In the same
study, metformin produced a weight loss of 2.9 kg in the
5 years.
The weight gain associated with TZDs is partly due to
oedema and fat. However, the increase in fat involves sub-
cutaneous fat more often than visceral fat.56 The oedema is
dose-dependent and is worst in combination with insulin.57
The oedema is refractory to loop diuretics but may respond
to spironolactone or hydrochlorothiazide treatment.58
This class should be avoided in the presence of heart
failure and liver disease.11 Liver function should be assessed
before starting these patients on this treatment and
periodically thereafter.11,59,60 TZD side effects are
summarized in Table 1.
Cardiovascular safety
The concern about heart failure was noted prior to TZD
marketing given that the premarketing trials excluded pa-
tients with class III and IV heart disease.61
Congestive heart failure occurs in less than 1% of patients
on rosiglitazone monotherapy but increases to 2% and 3%
upon the addition of 4 mg and 8 mg daily, respectively, with
comparable data for pioglitazone.61
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Association issued consensus statement regarding the use of
TZD and heart failure in 2003, urging clinicians to evaluate
heart disease patients prior to starting TZD and afterwards if
oedema develops. If the patient experiences heart failure,
treatment should be stopped.59e61
In June 2007, a meta-analysis of 42 trials concluded that
patients treated with rosiglitazone had a significant increase
in myocardial infarction (odds ratio ¼ 1.43 (95% CI 1.03e
1.98)) compared with controls, with insignificant increase in
cardiovascular mortality.62 This report spread panic across
the medical community. Before this report, the FDA was
ready to license the antidiabetic drug muraglitazar.
However, approval was declined after an independent
analysis revealed that the drug caused increased mortality
and major cardiovascular morbidity.63
In 2008, the FDA terminated a trial of intensive treatment
in diabetic patients with high cardiovascular risk aiming at
normalizing HbA1C after discovering that the intensive arm
exhibited increased mortality.64 After the preceding three
reports, the FDA revised the licensing process of diabetes
medications to include adequate cardiovascular studies
before and after licensing.27
In 2009, the Rosiglitazone Evaluated for Cardiac Out-
comes and Regulation of glycaemia in Diabetes (RECORD)
trial reported an increase in heart failure when rosiglitazone
was added to MET or SU compared with a combination of
MET and SU, but cardiovascular mortality was not
increased.65 A further re-evaluation of this trial as required
by the FDA with 328 additional person-years reported
similar results.66
Rosiglitazone was banned in Europe in 2010. The FDA
issued certain restrictions on its use. However, the re-
strictions were lifted in November 2013 after re-evaluation of
cardiovascular outcomes in the RECORD trial and obtain-
ing additional evidence that reduced their concern.66
However, the FDA continues to have uncertainties.67
Pioglitazone may be different regarding myocardial
infarction. Pioglitazone reduces fatal andnon-fatalmyocardial
infarction in patients with T2DM and previous myocardial
infarction,68 and a meta-analysis demonstrated that pioglita-
zone significantly reduced the risk of stroke, myocardial
infarction and death while increasing serious heart failure.69
Both rosiglitazone and pioglitazone increase the risk of
upper and lower limb fractures, especially in women, and
reduce bone mineral density.70,71
Pioglitazone increases the risk of bladder cancer68,72 and
was banned in Japan, India, Australia and Canada.
However, a recent study of a large cohort of 207,714
patients, including 23,548 who used pioglitazone, failed to
demonstrate a significant association between pioglitazone
use and the risk of bladder cancer.73
Dosage
The doses of pioglitazone and rosiglitazone and relation
to food consumption are presented in Table 2.
The NKF does not advise any change in the dose of TZDs
in patients with CKD.37 However, one must be careful if
these patients are oedematous as these drugs may worsen
the oedema, and these patients should be assessed for heart
failure.Alpha-glucosidase inhibitors
The first member of this group is acarbose, which was
approved by the FDA in 1995.
Mechanism of action and efficacy
Acarbose inhibits alpha-glucosidases at the intestinal
brush border.11 This process reduces carbohydrate
absorption and postprandial blood glucose. These drugs
exert a modest effect on diabetes control as a
monotherapy. In a meta-analysis of 28 trials, acarbose
reduced HbA1C by 0.77% versus controls.10 In the UKPDS
trial over a 3-year period, acarbose reduced the median
HbA1C by 0.5 compared with controls. However, only 39%
of patients completed the 3-year study on acarbose due to
side effects.74 In a Cochrane systematic review of 41 trials,
acarbose reduced HbA1C by 0.8% compared with placebo,
but most of the studies lasted only 24 weeks.75
The advantages of acarbose include being weight neutral
and the lack of hypoglycaemia. Acarbose acts at the level of
small intestine and does not have many systemic effects. It
appears to be more effective when the patient’s diet contains
large amounts of complex carbohydrates. A systematic meta-
analysis reported that acarbose was more effective in patients
on an Eastern diet (contains complex carbohydrates)
compared with those on a Western diet (contains processed
meats and refined carbohydrates).76
In an open study, the hypoglycaemic effect of acarbose as
monotherapy or in combination was sustained up to 5 years.77
Side effects and contraindications
The main side effects of acarbose are GI, such as
abdominal pain, bloating, flatulence, and diarrhoea, which
occur at different frequencies in different populations.11
In one study, the side effects occurred in 50% of patients
during the initial 4-week period and were only noted 13.8%
of patients during the last 4 weeks of a 24-week study.78
These GI side effects are dose-dependent.75 However,
these side effects may be quite troublesome in some
populations. In the UKPDS, 61% of the patients left the 3-
year study due to side effects.74 However, the drug appears
to be more tolerable in the East, with 2.03% of patients
experiencing side effects in a study involving patients from
the Far East, Middle East, Morocco and Poland.79
In a recent analysis of post-marketing data on more than
67,000 patients from 21 Asian and Caucasian countries, GI
side effects were present in 2.76% of patients, and acarbose
was only slightly more effective in South East and East
Asians.80 In this report, abnormal liver function tests, which
were reported in early trials, were observed in only 0.11% of
patients.
Acarbose is contraindicated in liver cirrhosis and in-
flammatory bowel disease.81 The side effects of acarbose are
summarized in Table 1.
Cardiovascular safety
We are not aware of large-scale controlled results
reporting the effect of acarbose on cardiovascular morbidity
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prevent T2DM in subjects with impaired glucose tolerance
was associated with a reduction of silent myocardial infarc-
tion.82 However, this result was noted in a sub-study analysis
of only 1181 patients. Moreover, the risk of cardiovascular
disease in pre-diabetes patients is not similar to that of pa-
tients with T2DM who develop abnormal coronary arteries
many years prior to the diagnosis of T2DM.
Dosage
The dose of acarbose and relation to food consumption
are summarized in Table 2. To reduce GI side effects, it is
advisable to start with 25 mg administered before each
meal. The dose is then increased to 50 mg and then 100 mg
after 4e8 weeks as needed and tolerated. Importantly,
doses greater than 50 mg for patients who weigh >60 kg
reduce the risk of increasing liver enzymes.81
Although acarbose is mainly metabolized by bacteria in
the intestinal tract and digestive enzymes, approximately
one-third of the dose may be absorbed and appears in the
urine.83 Thus, one must be careful when administered to
patients with renal impairment. The National Kidney
Foundation (NKF) advise avoiding acarbose if the GFR is
<30 ml/min/1.73 m2.37,81
Dipeptidyl peptidase-4 inhibitors
These compounds are based on the incretin effect in which
insulin secretion is modulated by a substance released from
the intestine into the circulation in response to food inges-
tion. In 1964, McIntyre and other researchers reported the
first proof that oral glucose induces more insulin secretion
than IV glucose based on alimentary mechanisms.84 Two
incretins are well characterized: the glucose-dependent
insulinotropic polypeptide (GIP) and the more potent
GLP-1. Both drugs exhibit glucose-dependent insulin stim-
ulation.85 GLP-1 inhibits glucagon secretion, delays gastric
emptying, and decreases appetite, causing weight loss in
addition to glucose-dependent insulin secretion. However,
GLP-1 is degraded rapidly by the enzyme dipeptidyl
peptidase-4 (DPP-4). Several inhibitors of this enzyme (DPP-
4I) have been synthesized. The first inhibitor, sitagliptin, was
approved by the FDA in 2006. Other inhibitors marketed in
KSA include vildagliptin, saxagliptin, and linagliptin.
Mechanism of action and efficacy
These agents modestly increase GLP-1 in the physiolog-
ical range. Thus, their effect on glucose reduction and weight
are not as notable as GLP-1 agonists. These agents do not
affect gastric emptying.86 These drugs induce glucose-
dependent insulin secretion in the first and second phases,
inhibit glucagon secretion and suppress hepatic gluconeo-
genesis.87 These agents rarely produce hypoglycaemia in
monotherapy and exhibit a weight-neural effect.88
In a systematic review, DPP-4I reduced HbA1C
compared with placebo with a WMD of 0.74 (95%
CI0.85 to0.62).89 Compared withMET as monotherapy,
these agents exhibited less reduction in HbA1C with WMD
of 0.20 (95% CI 0.08e0.32).90The durability of DPP-4I was reported in an observa-
tional study of sitagliptin in combination withMET in which
patients had a median of 43.2 months before requiring a
treatment change which was more than double the period
required by the combination of SU with MET.91 In another
study assessing sitagliptin in combination with MET, 72.2%
of patients responded after 1 year, and the response rate was
reduced to 35.4% at 4 years.92
This class of drugs is not recommended as the first-line
monotherapy. However, these drugs may be used in a
manner similar to other second-line agents if MET is con-
traindicated or not tolerated.7Side effects and contraindications
This class may produce allergic reactions as serious as
angioedema and anaphylaxis.93 Similarly, pancreatitis has
been rarely reported, and patients should be warned to
contact their physician immediately if they exhibit
continuous severe abdominal pain, which may radiate to
the back.94 Although a 5-year study of greater than 20,000
new users of incretins reported no increase in pancreatitis
compared with SU users,95 no large long-term controlled
studies have abolished the association with pancreatitis.
Vildagliptin may be associated with an increase in the liver
enzymes and is contraindicated in liver impairment. Trans-
aminases should be assessed prior to administer this drug,
and assessments should be repeated every 3 months during
the first year.96
Severe disabling arthralgia has been observed in this
group, and the FDA added a warning about this complica-
tion in August 2015.97 The side effects of DPP-4I are sum-
marized in Table 1.Cardiovascular safety
The Saxagliptin Assessment of Vascular Outcomes
Recorded in patients with DMeTIMI53 (SAVOR-TIME)
study was a large study that recruited 16,492 patients with or
at risk of cardiovascular disease who were randomized to
receive saxagliptin or placebo and followed up for a median
of 2.1 years. The study reported a significant increase in the
rate of admissions for heart failure in the saxagliptin group
compared with placebo with a hazards ratio of 1.27 (95% CI
1.07e1.51).98 Although this study revealed no increase in
ischaemic events, it raised concerns about cardiovascular
safety.
A network meta-analysis of 10 randomized trials
including 2967 patients found no significant difference be-
tween patients taking DPP-4I and placebo with regards to
mortality or cardiovascular disease.99 A recent observational
study of greater than 10,000 matched pairs on DPP-4I added
to MET and those on SU added to MET reported a reduced
risk of all-cause mortality and ischaemic stroke with DPP-4I.
However, concern regarding the cardiovascular safety of SU
has been noted for a long time. Moreover, DPP-4I did not
reduce myocardial infarction or admission for heart failure
compared with SU.100
The FDA conducted an on-treatment analysis of deaths
in patients on saxagliptin in SAVOR-TIME, and their results
suggest a significant or near significant increase in all-cause
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Drugs Advisory Committee of the FDA voted that sax-
agliptin labelling should include the potential increase in
heart failure, all-cause mortality, pancreatitis and impaired
renal function.101
The cardiovascular safety of DPP-4I has not been
demonstrated.
Dosage
The dose of DPP-4I and its relation to food intake are
presented in Table 2. In April 2015, the Endocrinologic and
Metabolic Drugs Advisory Committee discussed the
(SAVOR-TIMI) trials and commented on the observed
reduction in eGFR and improved albumin to creatinine
ration with saxagliptin with a low level of concerns. The
Committee considered these effects as a potential signal
that requires further study.101 The NKF recommends the
following dose adjustment in patients with CKD.37
Sitagliptin: Dose to be reduced to 50 mg daily if GFR is
30e50 ml/min/1.73 m2 or 25 mg if GFR <30.
Saxagliptin: reduce the daily dose to 2.5 mg if GFR is
50 ml/min/1.73 m2.
Vildagliptin: reduce the daily dose to 50 mg if GFR is
<50 ml/min/1.73 m2.
It is advisable to assess renal function prior to initiating
the above three medications and periodically thereafter. No
dose adjustment is needed for linagliptin.
Sodiumeglucose cotransporter-2 inhibitors
The kidney plays an important role in glucose homeo-
stasis via the enzyme sodiumeglucose cotransporter-2
(SGLT2), which reabsorbs sodium and glucose in the prox-
imal renal tubules. This enzyme may absorb approximately
90% of the 180 g of glucose filtered daily.102 Potent inhibitors
of this enzyme have been developed (SGLT2I).
Dapagliflozin was the first member of this group, which
was approved in Europe in 2012. Dapagliflozin was not
approved by the FDA initially due to concerns regarding the
risk of breast and bladder cancer. However, the drug was
approved in 2014 following more safety data.103
Canagliflozin was approved by the FDA in 2013.
Empagliflozin was approved in 2014. This group is new
discovered, and we are learning more about its efficacy and
side effects.
Mechanism of action and efficacy
These agents reduce blood glucose via a non-insulin-
dependent mechanism, namely glycosuria. Glycosuria is
accompanied by osmotic diuresis.
In addition to their inhibition of glucose reabsorption,
which aids in reducing blood glucose, glycosuria may result
in a loss of approximately 300 k/calories per day, which aids
in weight loss and improves insulin sensitivity.103
These agents induced significant reductions in HbA1C
compared with placebo, with a WMD of 0.66% (95%
CI0.73 to0.58), and weight, withWMD of1.7 kg (95%
CI 2.0 to 1.5).104 Compared with MET, sitagliptin and
SU, no significant difference in HbA1C was noted, butthese agents produced significant weight reduction with a
mean difference of 1.8 kg (95% CI 3.5 to 0.11). Due
to their recent introduction, no data on long-term dura-
bility are available. A meta-analysis reported that these
agents reduced HbA1C compared with placebo with aWMD
of0.49% for 1 year and 0.503% for 2 years. These agents
also reduced weight significantly with corresponding values
at 1 and 2 years of 2.47 kg and 2.990 kg, respectively.105Side effects and contraindications
The polyuria resulting from extra glucose in the urine may
produce dehydration with postural hypotension, especially
in the elderly and patients on diuretics. This effect may be of
particular concern in our hot countries during the summer
time.103
Glycosuria predisposes patients to urinary and genital
tract infections, especially females. At 2 years of treatment,
SGLT2I increased the risk of urinary tract and genital tract
infections with an odds ratio of 1.477 and 4.196, respec-
tively.105 Although these infections are cleared via simple
treatment,106 it is advisable to avoid using these agents in
patients with preceding recurrent urinary tract infections.
These results may produce a slight reduction of GFR.
GFR was reduced by 10.8%107 in patients on dapagliflozin,
but this condition is typically corrected in a short period of
time. The FDA drug labels advise assessing creatinine prior
to starting SGLT2I and periodically thereafter.108,109
Hyperkalaemia may develop after starting canagliflozin,
and serum potassium should be assessed before and peri-
odically after administration, especially in predisposed pa-
tients, such as those on spironolactone or ACE
inhibitors.109 The FDA has issued a safety podcast drawing
attention to the increase in bone fractures and decrease in
bone mineral density that may be associated with these
medications.110
Cases of euglycaemic diabetic ketoacidosis have been re-
ported with the use of SGLT2I.111 The majority of cases
exhibited type 1 diabetes mellitus or occurred with off-label
use in combination with insulin. It is advisable to evaluate
any patient on these medications for ketoacidosis if they
experience nausea and vomiting or malaise. The side effects
of SGLT-2I are summarized in Table 1.Cardiovascular safety
A meta-analysis of 14 dapagliflozin trials reported an
odds ratio for cardiovascular outcomes of 0.73 (95% CI
0.46e1.16) compared with controls.104 The same study
reported that canagliflozin cardiovascular outcomes were
observed with an odds ratio of 0.95 (95% CI 0.71e1.26)
compared with placebo or active comparators. In a study
of more than 7000 diabetic patients with high
cardiovascular risk followed for a median of 3.1 years,
empagliflozin significantly reduced death from
cardiovascular causes and admission for heart failure.112
Although these reports appear promising, reassuring large,
long-term controlled trials are not available. Moreover,
evidence suggests that SGLT1 cardiac expression increases
2- to 3-fold in patients with diabetes and cardiac ischaemia.
This effect may facilitate glucose entry into myocytes. As the
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guarantee that this inhibition will not be detrimental to the
heart under the above conditions.113
Dosage
Dapagliflozin is started at 5 mg daily without regards to
food. The maximum daily dose is 10 mg.108 The starting dose
of canagliflozin is 100 mg before the first meal, and the dose
may be increased as tolerated up to 300 mg daily.109
Empagliflozin is started as 10 mg in the morning, and the
dose may be increased to 25 mg if tolerated.114
Dapagliflozin should not be prescribed if the eGFR is
<60 ml/min/1.73 m2.108 Canagliflozin should not be
prescribed if the eGFR is <45 ml/min/1.73 m2.109 The
canagliflozin dose should not be greater than 100 mg if the
eGFR is 45 to less than 60 ml/min/1.73 m2.97
Empagliflozin should not be used if the eGFR is less than
45 ml/min/1.73 m2, and no dose adjustment is needed at or
above this eGFR.114
Judicious use of oral hypoglycaemic agents
There are many important factors that must be consid-
ered before making the therapeutic plan. These factors
include the following:
1. Degree of hyperglycaemia and the level of HbA1C: If
HbA1C is <7.5%, MET is the initial drug of choice (un-
less contraindicated) in addition to life-style modifica-
tion.7,115 When HbA1C is higher, the treatment becomes
more complex, but MET remains the basic drug to
which other medications are added. The AACE/ACE
advises dual therapy if entry HbA1C is 7.5%.
However the American Diabetes Association/European
Association for the Study of Diabetes (ADA/EUASD)
advises dual therapy when the HbA1C is 9%.7,115 Dual
therapy appears sensible when the entry HbA1C is7.5%
as MET is slightly less effective in controlling the fasting
blood glucose during the initial six months.116 The early
initiation of dual therapy is facilitated by the availability
of many oral agents with similar efficacies and low risks
of hypoglycaemia.
Triple therapy may be administered if dual therapy fails to
achieve the desirable control. Insulin is added to other
agents if the entry HbA1C is >9% with symptoms of
hyperglycaemia according to the AACE/ACE guidelines,
whereas ADA/EASD guidelines recommend initiating
combination with insulin injectable therapy when blood
glucose is 300 mg/dl (16.7 mmol/L) and/or HbA1C
10e12%. In such patients, treatment is simplified as the
glucose toxicity clears. The possibility of achieving an
HbA1C of less than 6.5% in a symptomatic patient with
an HbA1C of >9% by dual oral therapy is small.34 A
third drug is likely to contribute less than it would do in
mono- or dual therapy.117
Both guidelines advise moving from one stage to the next
if the target A1C is not achieved within 3 months. Basal
insulin, GLP-1 receptor agonists, SU, DPPI, TZD, and
SGLT2I may be used with MET in dual therapy, keeping
in mind comorbidities that may preclude the use of oneclass, e.g., TZD and DPPI should be avoided in patients
with heart failure.
2. Patient age and diabetes duration: In a young patient with
newly diagnosed diabetes with no comorbidities, one aims
for an HbA1C of<6.5%, and all needed combinations are
used. In a fragile old patient with long standing diabetes
with vascular complications and chronic illnesses, the
target HbA1C may be <8% or even <8.5%.7
3. Side effects of medications: The most important side effect
is hypoglycaemia. The AACE/ACE guidelines advise
caution when using SU or GLN across the 3 steps of
intensifying oral medications and consider both classes to
be the least favourable due to potential hypoglycaemia.115
Glinides may be used instead of SU in patients with
unpredictable food intake or those who develop late
postprandial hypoglycaemia with (SU).7
Another important side effect to consider is weight gain.
Weight gain ismore often observedwith SUandwithTZD,
and the combination is not favourable in obese patients.
4. Cost of medication: The target HbA1C was achieved in
the UKPDS with inexpensive medications, such as MET,
SU or insulin. Moreover, MET and SU are superior or at
least non-inferior to other expensive medications, have
been used for longer periods of time,10 and are available in
cheap generic formulae. If hypoglycaemia can be
prevented, this combination seems appropriate in our
developing countries. Table 2 presents the monthly cost
of different antihyperglycaemic agents.
5. Efficacy in reducing HbA1C: Most oral hypoglycaemic
agents reduce HbA1C by 1 absolute percentage point in
monotherapy. Dual therapy offers a greater reduction in
HbA1C of approximately 1 absolute percentage point
compared with monotherapy.10 As SU reduce HbA1C
compared with controls by a weighted mean absolute
difference of 1.52%,10 these drugs may be appropriate
in a young patient with moderately high glucose. In
these patients, TZDs may not be an appropriate starter
as they take several weeks to exert their full effects.55
The use of SU is most appropriate for patients with
T2DM with an onset within 5 years and no end-organ
involvement who are keen on adopting healthy lifestyle
with frequent blood glucose monitoring to reduce hypo-
glycaemia and weight gain.115 SGLT2Is are considered
2nd or 3rd line agents, and they may be used for insulin
sparing in T2DM patients on large doses of insulin.7
Guidelines now advise individualizing the treatment ac-
cording to all of the features of the case and taking into
consideration the preference of the patient. One should not
forget that insulin (basal) is a therapeutic option to add to
these medications in all of the stages after monotherapy.
It is important to stress here the importance of avoiding
threatening the patients that insulin injections will be added
if they do not adhere to diet and exercise for control. I have
witnessed physicians making this threat, which preconditions
the patients against insulin use when needed.Fixed drug combinations
Some companies produce formulae that contain MET in
addition to another medication. These drugs have been
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reduced pill burden. The bioavailability, tolerability and ef-
ficacy of these combinations were similar to the individual
components in dual therapy.118 Patients who switched from
dual therapy to fixed combination had a 12.4% increase in
adherence to medication.119 One of their major limitations
involves the lack of flexibility of the dose. In some
combinations, metformin is available in an extended
release formula. In other combination, it is available as an
immediate release formula, which may not be tolerated by
some patients.120
Conclusion
We now have a variety of antihyperglycaemic agents with
different mechanisms of action. Their use should be indi-
vidualized according to the health status and preference of
the patient, keeping in mind their efficacy and side effects.
Metformin remains the drug of choice in monotherapy, and
the others are added to it. However, SUs are becoming less
favourable as they may produce hypoglycaemia. Cardio-
vascular risk has received more attention and should be
investigated thoroughly before licensing newer agents.
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